Flag of the European Union EU Clinical Trials Register Help

Clinical trials for human insulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    322 result(s) found for: human insulin. Displaying page 14 of 17.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next»
    EudraCT Number: 2009-014618-80 Sponsor Protocol Number: CACZ885I2206 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident ath...
    Medical condition: atherosclerosis type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    14.1 10047065 - Vascular disorders 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000830-37 Sponsor Protocol Number: CP-4-005 Start Date*: 2013-07-03
    Sponsor Name:OPKO Biologics Ltd.
    Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency
    Medical condition: Adult or childhood onset growth hormone deficiency (GHD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000598-95 Sponsor Protocol Number: HS-20-674 Start Date*: 2021-07-30
    Sponsor Name:Camurus AB
    Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ...
    Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002624-28 Sponsor Protocol Number: FIT-EU-04 Start Date*: 2015-09-24
    Sponsor Name:Nutrinia Ltd.
    Full Title: A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants.
    Medical condition: Gastrointestinal Maturation in Preterm Infants.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000031-26 Sponsor Protocol Number: R256918DIA2001 Start Date*: 2007-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) NL (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001715-21 Sponsor Protocol Number: S59102 Start Date*: 2016-09-09
    Sponsor Name:UZ Leuven
    Full Title: Intravenous ketamine for Treatment Resistant Depression: Exploring biomarkers of response and relapse A double-blind, randomized controlled trial
    Medical condition: Major depressive disorder and Bipolar Disorder I and II
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005195 10037180 Psychiatric symptoms NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002468-26 Sponsor Protocol Number: DKprotokol(LIVE)v5 Start Date*: 2011-08-12
    Sponsor Name:Allan Flyvbjerg
    Full Title: Liraglutide in chronic heart failure. A randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and witho...
    Medical condition: Primary objective: To investigate the effect of Liraglutide 1.8 mg once daily compared to placebo on left ventricular eject fraction in Chromic heart failure patients with and without Type 2 diabe...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001915-22 Sponsor Protocol Number: CKN-DASI-RYGB Start Date*: 2019-09-05
    Sponsor Name:Center for Clinical Metabolic Research at Herlev-Gentofte Hospital
    Full Title: Dasiglucagon in the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10079748 Reactive hypoglycaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000929-42 Sponsor Protocol Number: TCH-306 Start Date*: 2021-06-09
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ...
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003100-39 Sponsor Protocol Number: NSGA Start Date*: 2013-11-28
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc...
    Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000203-82 Sponsor Protocol Number: SHP626-201 Start Date*: 2016-11-09
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter...
    Medical condition: Nonalcoholic steatohepatitis (NASH), is a clinical condition occurring in individuals who do not drink excessive alcohol (>20 grams/day), yet have hepatic histology which is indistinguishable from ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001364-72 Sponsor Protocol Number: EP00-402 Start Date*: 2008-01-04
    Sponsor Name:Sandoz GmbH
    Full Title: Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA)
    Medical condition: Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight and/or length be...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10018747 Growth hormone LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003815-46 Sponsor Protocol Number: 37826 Start Date*: 2012-05-15
    Sponsor Name:Erasmus MC
    Full Title: Double blind placebo controlled randomized intervention study aiming at reducing dexamethasone related side effects in children with acute lymphoblastic leukemia (ALL).
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10001690 ALL LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001850-16 Sponsor Protocol Number: 2016-001850-16 Start Date*: 2016-06-28
    Sponsor Name:University of Copenhagen, The Novo Nordisk Foundation Center For Basic Metabolic Research, Section of Metabolic Genetic
    Full Title: Studies of interplays between insulin resistance associated with immunosuppression and the gut and saliva microbiota composition of young, healthy men
    Medical condition: Young healthy men
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10062026 Investigation PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001061-29 Sponsor Protocol Number: NN8630-1823 Start Date*: 2008-06-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated lo...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-007725-46 Sponsor Protocol Number: ASBI 307 Start Date*: 2009-02-06
    Sponsor Name:Asubio Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 We...
    Medical condition: Cachexia associated with chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-004983-23 Sponsor Protocol Number: 201900874 Start Date*: 2021-01-18
    Sponsor Name:University Medical Center Groningen
    Full Title: Bioequivalence study of prednisolone and dexamethasone: corticosteroids revisited
    Medical condition: This study does not investigate a medical condition and is performed in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005395-35 Sponsor Protocol Number: GatesMRI-COD-01-T01-01 Start Date*: 2020-12-16
    Sponsor Name:Bill & Melinda Gates Medical Research Institute
    Full Title: A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19
    Medical condition: Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002623-11 Sponsor Protocol Number: 213500 Start Date*: 2020-12-18
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravi...
    Medical condition: Human Immunodeficiency Virus Type-1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed) AT (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002326-39 Sponsor Protocol Number: 1-10-72-57-15 Start Date*: 2015-08-19
    Sponsor Name:Gynecology Department,Herning Hospital [...]
    1. Gynecology Department,Herning Hospital
    2. Medical Department, Kolding Hospital
    Full Title: The influence of fat intake, estrogen, age, and gender on postprandial lipds and glucose
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:09:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA